Phenotyping for percutaneous coronary intervention and long-term recurrent weighted outcomes.

[1]  M. Alasnag,et al.  Baseline platelet count in percutaneous coronary intervention: a dose–response meta-analysis , 2022, Heart.

[2]  H. Nouraei,et al.  Comparison of Unsupervised Machine Learning Approaches for Cluster Analysis to Define Subgroups of Heart Failure with Preserved Ejection Fraction with Different Outcomes , 2022, Bioengineering.

[3]  E. Hagström,et al.  Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data , 2021, The Lancet.

[4]  C. Lowenstein,et al.  Inflammation and cardiovascular disease: From mechanisms to therapeutics , 2020, American journal of preventive cardiology.

[5]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[6]  Marco Valgimigli,et al.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.

[7]  Alejandro Lucia,et al.  Chronic inflammation in the etiology of disease across the life span , 2019, Nature Medicine.

[8]  R. Diaz,et al.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.

[9]  M. Sathyamoorthy,et al.  First and recurrent events after percutaneous coronary intervention: implications for survival analyses , 2019, Scandinavian cardiovascular journal : SCJ.

[10]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[11]  G. Billman,et al.  Inflammation–Nature's Way to Efficiently Respond to All Types of Challenges: Implications for Understanding and Managing “the Epidemic” of Chronic Diseases , 2018, Front. Med..

[12]  Kristian Thygesen,et al.  Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.

[13]  J. Spertus,et al.  Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document , 2018, Circulation.

[14]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[15]  S. Pocock,et al.  White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry) , 2017, Circulation. Cardiovascular interventions.

[16]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[17]  Lu Mao,et al.  Semiparametric regression for the weighted composite endpoint of recurrent and terminal events. , 2016, Biostatistics.

[18]  P. Armstrong,et al.  Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. , 2015, European heart journal.

[19]  D. Kamat,et al.  Erythrocyte sedimentation rate and C-reactive protein: how best to use them in clinical practice. , 2014, Pediatric annals.

[20]  N. Frangogiannis,et al.  The inflammatory response in myocardial injury, repair, and remodelling , 2014, Nature Reviews Cardiology.

[21]  E. Gilardi,et al.  Biomarkers in the prediction and management of acute coronary syndromes: current perspectives , 2014 .

[22]  Xavier Basagaña,et al.  A framework for multiple imputation in cluster analysis. , 2013, American journal of epidemiology.

[23]  Marie E. Latulippe,et al.  A Consideration of Biomarkers to be Used for Evaluation of Inflammation in Human Nutritional Studies , 2013, British Journal of Nutrition.

[24]  J. McMurray,et al.  Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials? , 2012, European heart journal.

[25]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[26]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[27]  Henri Luchian,et al.  A unifying criterion for unsupervised clustering and feature selection , 2011, Pattern Recognit..

[28]  L. Newby,et al.  Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. , 2007, American heart journal.

[29]  Virginie Rondeau,et al.  Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. , 2006 .